Positive data for the use of radioligand therapy in first-line neuroendocrine cancers

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

ASCO 2024: Lung cancer highlights

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma

PD-1–refractory advanced melanoma: how do we get to the finish line?

Highlights in melanoma from ASCO 2024

Immunotherapy significantly increases the number of patients free from bowel cancer

Encouraging results using mismatched unrelated donors in stem cell transplantation

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Importance of MRD in newly developed multiple myeloma

Best practice in HRRm testing in patients with metastatic prostate cancer

Cancer advocacy and fundraising in Nigeria

ASCO 2024: Lung cancer roundup

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

ASCO 2024: Highlights and analysis

ASCO 2024: Advances in NSCLC

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM

Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer

Osimertinib success in locally advanced EGFR-mutated NSCLC

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Adagrasib improves on docetaxel in previously treated NSCLC

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC

Manageable safety profile with early efficacy of Tec-DR in NDMM

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis

Melanoma outcomes improved by dual immunotherapy before surgery rather than after

Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer

Some advanced epithelial ovarian cancer patients can avoid a lymphadenectomy without impacting survival outcomes

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Looking at real world evidence on PSA testing in prostate cancer

Telehealth delivery of palliative care an effective alternative to in-person visits for patients with advanced lung cancer

Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma

Immunotherapy promise for gynaecologic extra-renal clear cell carcinomas

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Monitoring ovarian function in oncology studies

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM